CALC.NASDAQCalcimedica, INC

Form 4: CalciMedica CFO Stephen Bardin Increases Stake with Stock Purchase and Option Grant

Sentiment:

Insider Trading Report


CalciMedica, Inc.'s Chief Financial Officer, Stephen Bardin, has reported an acquisition of 2,000 shares of common stock and a grant of 20,000 employee stock options, signaling increased insider ownership.

Better than expectedThe purchase of common stock by a Chief Financial Officer is generally viewed as a positive signal, indicating management's belief in the company's undervaluation or strong future prospects.

Summary

  • Stephen Bardin, Chief Financial Officer of CalciMedica, Inc. (CALC), reported changes in his beneficial ownership.
  • On June 26, 2025, Mr. Bardin acquired 2,000 shares of CalciMedica Common Stock through a purchase (Code 'P') at a weighted average price of $1.5025 per share, with prices ranging from $1.45 to $1.54.
  • Following this transaction, Mr. Bardin beneficially owns 43,000 shares of Common Stock, comprising 3,000 shares held indirectly by The Bardin Family Trust dated June 4, 2024, and 40,000 shares held directly.
  • An earlier Form 4 filed on June 3, 2025, inadvertently reported 1,000 shares held by the Trust as directly owned.
  • On June 24, 2025, Mr. Bardin was granted 20,000 employee stock options (Right to Buy) with an exercise price of $1.53 per share.
  • These options are immediately exercisable and have an expiration date of April 22, 2035.
  • The option grant was approved by CalciMedica's Board of Directors on April 23, 2025, contingent on stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan, which was obtained on June 24, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the insider purchase of common stock and the grant of options, which aligns management's interests with shareholders. This typically signals confidence from within the company.

Positives

  • The Chief Financial Officer's purchase of 2,000 shares of common stock at an average price of $1.5025 indicates management's confidence in the company's future prospects.
  • The grant of 20,000 employee stock options aligns the CFO's incentives with shareholder interests, as the options become more valuable with an increase in the company's stock price.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This filing is a routine insider transaction disclosure and does not provide broader industry context or trends. It reflects an individual executive's investment decision within the company.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Plan Amendment ApprovalStockholders approved an amendment to the Company's 2023 Equity Incentive Plan (Amended 2023 EIP), under which the employee stock options were granted.06/24/2025This approval enables the company to continue granting equity incentives to employees, aligning their interests with long-term shareholder value and supporting talent retention and attraction.

Related Party Transactions

  • Shares are held indirectly by The Bardin Family Trust dated June 4, 2024, which is a related party to the reporting person.

Stakeholder Impact

  • Shareholders may view the CFO's stock purchase as a positive indicator of management confidence, potentially influencing investor sentiment.
  • Employees, particularly those participating in equity incentive plans, benefit from the continued operation and amendment of such plans, which can enhance compensation and retention.

Key Dates

DateDescription
06/04/2024Date of The Bardin Family Trust.
04/23/2025CalciMedica's Board of Directors approved the employee stock option grant, subject to stockholder approval.
06/03/2025Previous Form 4 filed with the SEC, which contained an inadvertent reporting error regarding directly owned shares.
06/24/2025Stockholders approved the Amended 2023 Equity Incentive Plan; Earliest transaction date for the employee stock option grant.
06/26/2025Date of common stock purchase transaction; Date of Form 4 filing.
04/22/2035Expiration date of the employee stock options.

Keywords

CalciMedica, CALC, SEC Form 4, Insider Trading, Stock Purchase, Stock Option, Stephen Bardin, Chief Financial Officer, Beneficial Ownership, Equity Incentive Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.